A Case Report of Potato Allergy With Atypical Manifestations in a 2-Year-Old Child
Abstract
Food allergies are an increasing global health concern, affecting up to 6%–8% of children and 3%–4% of adults. While common allergens such as milk, eggs, and peanuts are well‐documented, rare food allergies, such as those to potatoes, remain underrecognized. Potatoes, a staple food worldwide, can trigger allergic reactions in susceptible individuals due to proteins like patatin (Sol t 1) and protease inhibitors. This case report describes a two‐year‐old child presenting with recurrent gastrointestinal and respiratory symptoms, ultimately diagnosed with a potato allergy. The child exhibited intermittent vomiting, diarrhea, and wheezing, with episodes temporally linked to potato consumption. Initial clinical evaluations, including hydration and dietary modifications for lactose intolerance or viral gastroenteritis, provided temporary relief but failed to address the underlying cause. A worsening pattern of symptoms, including perioral redness and worsening wheezing, prompted referral to a pediatric allergist. Diagnostic workup revealed elevated eosinophil counts, increased total IgE levels, and significant skin prick test (SPT) reactivity to potato extract. Serum‐specific IgE testing confirmed sensitization to Sol t 1. Management included a strict potato‐free diet, with additional precautionary exclusion of cross‐reactive foods within the Solanaceae family. This intervention led to complete resolution of symptoms, improved weight gain, and enhanced quality of life. Long‐term…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Patient-Centered Pharmaceutical Design to Improve Acceptability of Medicines: Similarities and Differences in Paediatric and Geriatric Populations
- Evidence-based clinical practice guidelines for irritable bowel syndrome 2020
- Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial
- Gastrointestinal manifestations in COVID-19
- COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist
- Persistent gut barrier damage and commensal bacterial influx following eradication of Giardia infection in mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.